Short-term impact of intravitreal ranibizumab injection on axial ocular dimension and intraocular pressure

Cutaneous and Ocular Toxicology

Volumn 32, Issue 1, 2013, Pages 23-26

  Goktas, Altan ^a   Goktas, Sertan ^b   Atas, Mustafa ^a   Demircan, Suleyman ^a   Yurtsever, Yusufcan ^a  

^a Training and Research Hospital ^*  (Turkey)

^b Tekden Hospital   (Turkey)

Author keywords

Biometry; Intraocular pressure; Intravitreal injection; Ranibizumab

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ARTICLE; AXIAL OCULAR DIMENSION; BIOMETRY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EYE EXAMINATION; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MALE; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; SHORT COURSE THERAPY; SLIT LAMP; SUBRETINAL NEOVASCULARIZATION; TONOMETER; VISUAL SYSTEM PARAMETERS;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMETRY; EYE; FEMALE; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED;

EID: 84868597393     PISSN: 15569527     EISSN: 15569535     Source Type: Journal    
DOI: 10.3109/15569527.2012.696569     Document Type: Article

References (13)

1. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011;56:95-113
2. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina (Philadelphia, Pa) 2006;26:859-870
3. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al.; MARINA Study Group. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med 2006;355:1419-1431
4. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al.; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444
5. Sharei V, Höhn F, Köhler T, Hattenbach LO, Mirshahi A. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis). Eur J Ophthalmol 2010;20:174-179
6. Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusini P. Shortterm effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 2009;18:658-661
7. Leydolt C, Findl O, Drexler W. Effects of change in intraocular pressure on axial eye length and lens position. Eye (Lond) ;22:657-661
8. Read SA, Collins MJ, Annis-Brown T, Hayward NM, Lillyman K, Sherwin D et al. The short-term influence of elevated intraocular pressure on axial length. Ophthalmic Physiol Opt 2011;31:398-403
9. Hill WE. The IOLMaster. Tech Ophthalmol 2003;1:62-7
10. Höhn F, Mirshahi A. Impact of injection techniques on intraocular pressure (IOP) increase after intravitreal ranibizumab application. Graefes Arch Clin Exp Ophthalmol 2010;248:1371-1375
11. Meyer CH, Holz FG. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: Ranibizumab and bevacizumab. Eye (Lond) ;25:661-672
12. Buchanan RA, Williams TD. Intraocular pressure, ocular pulse pressure, and body position. Am J Optom Physiol Opt 1985;62:59-62
13. Kotliar K, Maier M, Bauer S, Feucht N, Lohmann C, Lanzl I. Effect of intravitreal injections and volume changes on intraocular pressure: Clinical results and biomechanical model. Acta Ophthalmol Scand 2007;85:777-781.